Testosterone Cypionate Injection-Site Pain: A Severity Grading Rubric

What was wrong with the old rubric

The previous page assigned Grade 1, 2, or 3 using exact 48-hour, 72-hour, and 2.5-centimeter cutoffs. It then mapped those grades to cold packs, needle sizes, subcutaneous dosing, antibiotics, drainage, or a treatment hold. Those thresholds and actions were not taken from a testosterone cypionate trial or the current product label.

Seven displayed PubMed IDs also resolved to unrelated research: infant home visitation, a prostate genomic score, birdsong analysis, pediatric vaccination needle size, urinary sodium, an HIV clinic cohort, and Polish cardiac technology policy. The page further attributed a quotation to Shalender Bhasin that does not appear in the cited Endocrine Society guideline. The quotation and every unsupported result have been removed.

What the label establishes

The current Depo-Testosterone label lists “inflammation and pain at the site of intramuscular injection” among adverse reactions [1]. It describes testosterone cypionate in cottonseed oil with benzyl benzoate and benzyl alcohol and directs intramuscular administration deep in the gluteal muscle. It does not provide:

• A 5% to 10% injection-pain incidence
• A claim that most reactions resolve in 24 to 48 hours
• A 2.5-centimeter redness threshold
• A needle-gauge pain reduction percentage
• A normal 3-to-14-day depot nodule rule
• An instruction to warm, cool, or massage the injection site
• A home antibiotic or dose-hold protocol

That distinction protects readers from false reassurance and unnecessary treatment changes.

A practical three-level communication framework

This framework borrows the NCI CTCAE's broad concepts of mild, moderate, and severe functional impact. It does not reproduce CTCAE as a self-diagnosis. NCI explains that CTCAE is terminology for documenting adverse events in clinical trials, with grade-specific definitions for each event [4]. It is not a substitute for examining a possible infection, hematoma, nerve injury, or allergic reaction.

Level 1: mild and improving

The symptom is localized, mild, not spreading, and clearly improving. Normal walking, sitting, sleep, and daily activity are not meaningfully limited. There is no fever, drainage, generalized rash, breathing problem, or progressive swelling.

Record the product, dose volume, route, site, time, and symptom course. Before another injection, confirm that the site is no longer tender, red, bruised, swollen, or hard. If the symptom recurs, show the record to the prescriber rather than assuming repeated reactions are normal.

Level 2: persistent, recurrent, or activity-limiting

The symptom is not clearly improving, keeps returning, or interferes with walking, sitting, sleep, work, exercise, or use of the limb. The site may remain tender, bruised, swollen, or hard. This level calls for a prescriber review, not an automatic needle, route, oil, dose, or schedule change.

Ask the clinician to verify the exact product and concentration, labeled route, anatomical site, injection depth, aseptic technique, bleeding risk, storage, visible product quality, and whether a manufacturer or excipient changed. MedlinePlus recognizes pain, redness, bruising, bleeding, or hardness at a testosterone injection site and advises contacting a clinician when symptoms are severe or do not go away [2].

Level 3: severe, progressive, systemic, or emergency symptoms

Severe pain, rapidly worsening swelling, expanding redness, red streaks, drainage, marked warmth, fever, or feeling ill needs prompt medical evaluation. A clinician may need to distinguish cellulitis or abscess from bleeding, sterile inflammation, hypersensitivity, or another diagnosis. The IDSA skin and soft-tissue infection guideline addresses clinician diagnosis and treatment; it does not support prescribing a fixed antibiotic regimen from a website [5].

Trouble breathing, swelling of the lips, mouth, or face, or a generalized itchy rash after an injection requires emergency help [3]. Do not wait for a circumference or elapsed-time cutoff.

How to document the reaction

Use the same fields after each event:

1. Exact product, manufacturer, strength, dose volume, route, and site.
2. Who administered it and whether any technique problem occurred.
3. Onset and direction: improving, unchanged, or worsening.
4. Pain and its effect on walking, sitting, sleeping, or self-care.
5. Redness or swelling: localized, stable, or expanding.
6. Bruising, hardness, drainage, warmth, itching, rash, or red streaks.
7. Temperature and any systemic illness or breathing symptom.
8. A dated photograph when it can help show progression.

This gives a clinician more useful information than labeling the event “Grade 2” from a ruler measurement.

Do not turn the rubric into a treatment calculator

Needle and site changes

The old page claimed a randomized adult testosterone trial showed a 46% pain reduction with a 25-gauge needle. The cited record was a Cochrane review of vaccination needle size in children and adolescents, not testosterone cypionate [6]. General intramuscular technique evidence exists, but the correct needle and site depend on the exact product, intended tissue, patient anatomy, and clinician training [7].

Depo-Testosterone is labeled for deep gluteal intramuscular use [1]. Do not infer that deltoid, thigh, ventrogluteal, dorsogluteal, or abdominal injection instructions are interchangeable across products.

Subcutaneous route

Small studies provide a real basis for discussion. A 14-person crossover pilot found comparable testosterone exposure and lower reported injection pain during a subcutaneous phase using testosterone cypionate or enanthate in transgender adults [8]. A 63-person retrospective cohort reported minor transient local reactions in 9 participants and strong preference for subcutaneous administration among those who switched from intramuscular therapy [9].

Those studies do not support the old claim of a 232-man cohort with a 50% reduction in pain, and they do not rewrite the Depo-Testosterone label. A route change requires the prescriber to specify the exact product, dose, supplies, training, and monitoring.

Antibiotics, drainage, and treatment holds

Do not self-start cephalexin or any antibiotic from a severity score. Cellulitis, abscess, hematoma, sterile inflammation, and allergy can look similar without examination, yet require different management. Incision and drainage is a medical procedure. Whether to delay testosterone while a site is evaluated is also an individualized prescriber decision.

Carrier oil and compounding

Pain alone cannot identify cottonseed-oil allergy. A verified 2024 report documents delayed hypersensitivity to testosterone cypionate injections, but one case does not establish frequency or the responsible ingredient in another patient [10]. Recurrent itching, plaques, rash, or swelling should be evaluated with the exact vial and ingredient list.

Compounded grapeseed or MCT-oil products are not automatically safer or equivalent. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality [11]. Product switching belongs in a clinician-pharmacist plan, not a grade-based website instruction.

A clearer action table